# ProMIS Neurosciences Inc. Common Shares (ON) (PMN)

> ProMIS Neurosciences Inc. Common Shares (ON) (PMN) trades at $3.42 (+0.29%) as of 3:55:38 PM EST on Nov 4, 2026, -62.87% over the past month. Market cap is $30.58M, with 7.1 days to cover in short interest.

Canonical: https://massive.com/quote/pmn
Data as of: 2026-11-04T20:55:38.115Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$3.42** +0.01 (+0.29%)
As of 3:55:38 PM EST on Nov 4, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How ProMIS Neurosciences Inc. Common Shares (ON) (PMN) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +0.29% |
| 1W | -69.11% |
| 1M | -62.87% |
| YTD | -49.89% |
| 1Y | -66.63% |
| 52-wk range | $2.78 – $27.40 |

From daily closes through Nov 4, 2026.

## Key statistics

Today's trading snapshot for PMN: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $3.02 – $3.54 |
| Open | $3.41 |
| Prev close | $3.41 |
| Volume | 458.65K |
| Market cap | $30.58M |
| Shares out | 8.97M |

## Valuation and profitability ratios

Valuation and profitability ratios for ProMIS Neurosciences Inc. Common Shares (ON): P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | — |
| P/B | 0.62 |
| P/FCF | — |
| ROE | -85.5% |
| ROA | -74.5% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 3, 2026

## Insider trading

[ProMIS Neurosciences Inc. Common Shares (ON) (PMN) insider trading](https://massive.com/quote/pmn/insider-trading.md): open-market Form 4 buys and sells by ProMIS Neurosciences Inc. Common Shares (ON) insiders over the last 12 months.

## 8-K filings

Material corporate events ProMIS Neurosciences Inc. Common Shares (ON) has disclosed to the SEC on Form 8-K.

- Jul 28, 2026 · Investor presentation
  “On July 28, 2026 at 8:00 a.m. E.T., the Company will host a virtual webinar featuring key opinion leaders Dr. Will Mantyh, Associate Professor with Tenure, University of Minnesota Medical School and Dr. Michael Weiner, Professor Emeritus, University of California, San Francisco, to discuss the Company's six-month blinded interim data from the PRECISE-AD Phase 1b trial evaluating PMN310 in patients with early Alzheimer's disease. A copy of the presentation from the event will be available in the 'Investors' section of the Company's website.”
- May 20, 2026 · Equity compensation grant
  “The stockholders of ProMIS Neurosciences Inc. approved an amendment (the '2025 Plan Amendment') to the Company's 2025 Stock Option and Incentive Plan (the '2025 Plan')... The 2025 Plan Amendment increases the number of Common Shares available for issuance thereunder the 2025 Plan by 900,000 Common Shares.”
- Jan 30, 2026 · Private placement
  “On January 29, 2026, ProMIS Neurosciences Inc. (the "Company") entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with selected investors that qualify as "accredited investors" (the "PIPE Investors"), as defined in Rule 501(a) of Regulation D promulgated under the United States Securities Act of 1933, as amended (the "Securities Act"), for the purpose of raising approximately $75 million in aggregate gross proceeds for the Company (the "Offering") before deducting placement agent fees and other expenses payable by the Company.”
- Dec 16, 2025 · [Listing compliance regained](https://massive.com/quote/sec-filings/8-k/delisting-notices.md)
  “On December 12, 2025, ProMIS Neurosciences Inc. (the "Company") received a written notification from the Nasdaq Stock Market Listing Qualifications Staff indicating that the Company has regained compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market ("Nasdaq") pursuant to NASDAQ Listing Rule 5550(a)(2) ("Bid Price Rule") and that the matter is now closed.”
- Nov 24, 2025 · [Stock split](https://massive.com/quote/sec-filings/8-k/stock-splits.md)
  “On November 17, 2025, the Board approved a reverse stock split of the Common Shares at a ratio of one-for-twenty-five. Effective as of 12:01 a.m. Eastern Time on November 28, 2025, the Company filed the Articles Amendment to effect one-for-twenty-five reverse stock split of its Common Shares (the 'Reverse Stock Split'). As a result of the Reverse Stock Split, every 25 Common Shares issued or outstanding were automatically reclassified into one validly issued, fully-paid and non-assessable new Common Share.”

## Dividend history and stock splits

ProMIS Neurosciences Inc. Common Shares (ON)'s recent dividend payments and stock splits.

### Dividends

No recent dividends.

### Splits

- 1-for-25 · Nov 28, 2025

## PMN short interest

How heavily PMN is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 7.1 |
| Short interest | 245.84K |
| Avg volume | 34.43K |

As of Oct 15, 2026 · reported to FINRA twice monthly.

## PMN news

The latest news and headlines about ProMIS Neurosciences Inc. Common Shares (ON) (PMN).

- [Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs \| DelveInsight](https://www.globenewswire.com/news-release/2026/10/22/3386781/0/en/alzheimer-s-disease-clinical-trial-and-competitive-landscape-enters-a-new-phase-as-200-companies-advance-clinical-programs-delveinsight.html) · GlobeNewswire Inc. · Oct 22, 2026 · positive sentiment
- [ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial](https://www.globenewswire.com/news-release/2026/07/28/3334059/0/en/ProMIS-Neurosciences-Reports-Positive-Blinded-Six-Month-Interim-Safety-and-Biomarker-Data-for-PMN310-in-the-PRECISE-AD-Phase-1b-Alzheimer-s-Disease-Trial.html) · GlobeNewswire Inc. · Jul 28, 2026 · positive sentiment
- [ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026](https://www.globenewswire.com/news-release/2026/07/14/3326583/0/en/ProMIS-Neurosciences-Reports-First-Human-Evidence-of-Amyloid-Beta-Oligomer-Target-Engagement-by-PMN310-at-AAIC-2026.html) · GlobeNewswire Inc. · Jul 14, 2026 · positive sentiment
- [ProMIS Neurosciences Announces Reverse Stock Split](https://www.globenewswire.com/news-release/2025/11/24/3193417/0/en/ProMIS-Neurosciences-Announces-Reverse-Stock-Split.html) · GlobeNewswire Inc. · Nov 24, 2025 · neutral sentiment
- [ProMIS Neurosciences Announces Private Placement Financing](https://www.globenewswire.com/news-release/2025/07/28/3122321/0/en/ProMIS-Neurosciences-Announces-Private-Placement-Financing.html) · GlobeNewswire Inc. · Jul 28, 2025 · positive sentiment

## About ProMIS Neurosciences Inc. Common Shares (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 11 |
| Listed | Sep 30, 2005 |

[Company website](https://www.promisneurosciences.com)

## FAQ

### What is the ProMIS Neurosciences Inc. Common Shares (ON) (PMN) stock price today?

ProMIS Neurosciences Inc. Common Shares (ON) (PMN) is trading at $3.42 (+0.29% on the day) as of 3:55:38 PM EST on Nov 4, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is ProMIS Neurosciences Inc. Common Shares (ON)?

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and…

### What is the short interest in PMN?

As of Oct 15, 2026, PMN has 245.84K shares short and 7.1 days to cover.

### What exchange is PMN listed on?

ProMIS Neurosciences Inc. Common Shares (ON) (PMN) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time PMN quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=PMN`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [ProMIS Neurosciences Inc. Common Shares (ON) (PMN) insider trading](https://massive.com/quote/pmn/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms